Torrent Pharmaceuticals Limited

Ramesh Chandra Gupta

Laxmikant Chhipa

Chaitanya Dutt

Vijay Chauthaiwale

Shailesh Deshpande

Sanjay Srivastava

Shitalkumar Pukharaj Zambad

Jaya Abraham

Jignesh Kotecha

Anita Chaudhari

Ashok Kasundra

Anookh Mohanan

Murali Badanthadka

Prashant G Jamadarkhana

Davinder Tuli

Siralee Munshi

M Amir Siddiqui

Subrat Kumar Bhattamisra

Ram Gupta

Vivek Mishra

Amit Kesarwani

Sachin Latad

Manish Patel

Shital Kumar Zambad

Anoop Mathur

C Dutt

Mohan Singaravel

The present invention is directed to methods of producing substituted pyrazole based compounds through novel intermediates and unique processes for preparing such intermediates which enables synthesis of final product through commercially viable route of synthesis. The present invention is also directed to novel methods of producing substituted pyrazole based thyroid like compounds, and solid forms of 3-{4-[(7-hydroxy-6-methyl-indan-4-yl)methyl]-3,5-dimethyl-1H-pyrazol-1-yl}-propanoic acid, its pharmaceutical compositions, and methods of preparation thereof.

Methods of producing pyrazole compounds

This invention relates to pharmaceutical formulations comprising 1-(2-thien-2'-yl-2-oxo-ethyl)-3-(methanesulfonyl hydrazine carbonyl) pyridinium, its pharmaceutically acceptable salts, salt-cocrystals and co-crystals, particularly 1-(2-thien-2&#x2032;-yl-2-oxo-ethyl)-3-5(methanesulfonyl hydrazine carbonyl) pyridinium chloride. The formulations are suitable for oral administration and also comprise a permeability enhancer or a suitable base or a mixture thereof. The formulations of this invention are for treating diseases associated with advanced glycation end products.

Pharmaceutical formulations

Present invention relates to a low dose pharmaceutical composition, preferably oral composition comprising therapeutically effective amount of [(2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H,5H-10-thia-1,4a-diaza-benzo[a]azulene-3-carbonyl)-amino]-acetic acid (compound A) in the range of 2.5 mg to 60 mg. Present invention also relates to a method of treating inflammatory bowel disease in a mammal by administrating said low dose pharmaceutical composition. Further, present invention relates to a use of the compound A for the preparation of low dose pharmaceutical composition for the treatment of inflammatory bowel disease in a mammal.

Low dose pharmaceutical composition

Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease

The present invention relates to novel compounds, their pharmaceutically acceptable salts, and their isomers, steroisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses pharmaceutically acceptable compositions of said compounds and process for preparing novel compounds. The invention further relates to the use of the above-mentioned compounds for the preparation of medicament for use as pharmaceuticals.

Fused thiazolo and oxazolo pyrimidinones

The present invention relates to novel compounds, their pharmaceutically acceptable salts, and their isomers, stereoisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses pharmaceutically acceptable compositions of said compounds and process for preparing novel compounds. The invention further relates to the use of the above-mentioned compounds for the preparation of medicament for use as pharmaceuticals.

The present invention discloses a novel thyroid like compounds of formula (I), wherein RR2, R, Rand Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome. 

Pyrazole-based thyroid receptor compounds

A novel thyroid like compounds of formula (I), wherein R, R, R, Rand Z are as defined in the specification, method for its preparation, composition and use thereof. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions including obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome. 

Thyroid like compounds

Growing community of inventors

Gandhinagar, India

Ramesh Chandra Gupta